2021 American Transplant Congress
Outcomes of IVIG Monotherapy for Donor-Specific Antibodies After Lung Transplantation
Vanderbilt University Medical Center, Nashville, TN
*Purpose: De novo donor-specific antibodies (DSA) are a risk factor for antibody mediated rejection (AMR) and poor clinical outcomes after lung transplant (LT). Intravenous immune…2021 American Transplant Congress
Nomogram of Quantity of Peripheral Cxcr5+Cd8+ T Cells, Aims to Predict Risk of De Novo Dsa in First-time Kidney Transplant Recipients
1OSU, Columbus, OH, 2Center for Biostatistics, OSU, Columbus, OH
*Purpose: We recently reported that peripheral CXCR5+CD8+ T cells are inversely associated with the risk of developing de novo DSA (dnDSA) in the first year…2021 American Transplant Congress
Non-HLA Antibodies and Eplet Mismatches in Cases with Histological Picture of Antibody-Mediated Rejection with and without HLA Donor-Specific Antibodies
*Purpose: Correlation between antibody-mediated rejection (ABMR) and HLA donor-specific antibodies (DSA) is strong but imperfect in kidney transplant (KT) recipients, raising the possibility of other…2021 American Transplant Congress
Limited Immunogenicity of a Single Dose of Sars-cov-2 Mrna Vaccine in Solid Organ Transplant Recipients
*Purpose: Given substantial challenges with vaccine allocation and evidence for short-term vaccine efficacy after a single dose of SARS-CoV-2 mRNA vaccines in clinical trials, some…2021 American Transplant Congress
Cellular and Genetic Signatures of Operational Tolerance in Kidney Transplant Recipients Through Single Cell R N A Sequencing Analysis
*Purpose: Patients with operational tolerance do not use immunosuppressants after renal transplantation, but they show stable post-transplant results. We analyzed differently expressed mRNAs and proteins…2021 American Transplant Congress
Monoclonal Antibodies for Covid-19 in Patients with Solid Organ Transplant Recipients
*Purpose: The FDA has issued Emergency Use Authorization (EUA) for monoclonal antibodies for the treatment of mild to moderate COVID-19 in patients at risk for…2021 American Transplant Congress
Efficacy of MAU868, a Novel BKV Neutralizing Monoclonal Antibody (mAb), for the Treatment of Severe BK Virus Nephropathy (BKVN) After Kidney Transplant
*Purpose: BKV reactivation leading to nephropathy and allograft loss in kidney transplant (KT) recipients remains a clinical significant concern. No specific or effective anti-BKV therapies…2021 American Transplant Congress
Immune Response to Covid-19 in Kidney Transplant Waitlist Patients
1Baylor College of Medicine, Houston, TX, 2Baylor St. Luke's Medical Center, Houston, TX
*Purpose: The purpose of this study was to determine the effect of SARS-CoV-2 infection on the immune response in Kidney Transplant Waitlist Candidates (KTWC) and…2021 American Transplant Congress
Quantification of Multiple Isotypes of Anti-SARS-CoV-2 Antibodies in Kidney Transplant Recipients
*Purpose: Solid organ transplant recipients are at increased risk of severe outcomes with infection by SARS-CoV-2, the etiologic agent of COVID-19. Antibodies directed against the…2021 American Transplant Congress
Impaired Antibody Responses to Spike Protein Antigens of Sars-cov-2 in Solid Organ Transplant (sot) Recipients
*Purpose: Chronic immunosuppression can impair antibody responses after natural infection and vaccination in SOT recipients. It is not known whether antibody responses are impaired in…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 57
- Next Page »